| Study ID |
# Subjects Enrolled |
Summary of Findings |
| Subjects treated with Ta1 |
| Wu 2012 [84] |
367 |
• 28-day mortality decreased (26% vs. 35%; p=0.062 or 0.049)
• Relative risk of death decreased (0.74)
• mHLA-DR increased more |
| Chen 2007 [85] |
42 |
• 28-day cumulative survival increased (18/21 vs. 12/21 placebo; p<0.01)
• Shortened length of mechanical ventilation, use of antibiotics, stay in ICU |
| Zhao 2007 [86] |
42 |
• Improvement in lymphocytes, mHLA-DR, IL-10 (p<0.05)
• Decrease in inflammation marker IL-6 |
| Li 2009a [87] |
91 |
• Improvement in Marshall and APACHE II scores and immune parameters
• Shortened length of mechanical ventilation and stay in ICU |
| Wang 2010 [88] |
24 |
• Subjects had severe acute pancreatitis
• Decreased 28-day infection rate (p=0.012)
• Decreased sepsis (p=0.036)
• Shorter duration of ICU stay (p=0.014)
• Decreased rate of surgery (p=0.036)
|
| Subjects treated with Ta1 plus PI |
| Lin 2007 [89] |
342 |
• 28-day mortality decreased (25.1 vs. 38.3; p=0.0088)
• 90-day mortality decreased (37.1 vs. 52.1; p=0.0054)
• APACHE II decreased (p=0.0382)
• mHLA-DR increased
|
| Zhang 2008 [90] |
120 |
• 28-day survival increased (51.7 vs. 33.9; p=0.086)
• APACHE II improved (p<0.001)
• Shortened length of mechanical ventilation, use of dopamine, stay in ICU (p<0.001)
• Incidence of shock decreased (p=0.026)
|
| Li 2009b [91] |
56 |
• 28-day survival increased (78 vs. 60%; p<0.05)
• APACHE II improved |
| Chen 2009 [92] |
114 |
• 28-day survival increased (54.1 vs. 35.4; p=0.078)
• 60-day survival increased (54.1 vs. 28.2; p=0.045)
• 90-day survival increased (47.4 vs. 20.0; p=0.033)
• APACHE II improved significantly
• Shorter stay in ICU, duration of supportive ventilation, dopamine, and antimicrobial therapy |
| Huang 2009 [93] |
70 |
• 28-day survival increased (63.9 vs. 41.2; p<0.05)
• Average survival time increased from 245 to 342 days
• mHLA-DR increased more |
Abbreviations: APACHE II = Acute Physiology and Chronic Health Evaluation; ICU
= intensive care unit; mHLA = monocyte human leukocyte antigen; PI = protease
inhibitor; Ta1 = thymosin alpha 1; vs. = versus